Corcept Therapeutics Incorporated (0I3Q.L)
USD 55.58
(-0.47%)
USD 55.58
(-0.47%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 482.37 Million USD | 20.04% |
| 2022 | 401.85 Million USD | 9.8% |
| 2021 | 365.97 Million USD | 3.42% |
| 2020 | 353.87 Million USD | 15.46% |
| 2019 | 306.48 Million USD | 21.99% |
| 2018 | 251.24 Million USD | 57.82% |
| 2017 | 159.2 Million USD | 95.77% |
| 2016 | 81.32 Million USD | 61.72% |
| 2015 | 50.28 Million USD | 89.39% |
| 2014 | 26.55 Million USD | 156.36% |
| 2013 | 10.35 Million USD | 213.18% |
| 2012 | 3.3 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 29 Thousand USD | -86.12% |
| 2008 | 209 Thousand USD | -56.64% |
| 2007 | 482 Thousand USD | 63.95% |
| 2006 | 294 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 146.8 Million USD | 8.42% |
| 2024 Q2 | 163.79 Million USD | 11.57% |
| 2024 Q3 | 182.54 Million USD | 11.45% |
| 2023 Q3 | 123.6 Million USD | 5.0% |
| 2023 Q1 | 105.65 Million USD | 2.52% |
| 2023 FY | 482.37 Million USD | 20.04% |
| 2023 Q2 | 117.71 Million USD | 11.42% |
| 2023 Q4 | 135.4 Million USD | 9.55% |
| 2022 Q3 | 101.72 Million USD | -1.6% |
| 2022 Q1 | 93.68 Million USD | -5.2% |
| 2022 Q4 | 103.05 Million USD | 1.31% |
| 2022 FY | 401.85 Million USD | 9.8% |
| 2022 Q2 | 103.38 Million USD | 10.35% |
| 2021 Q4 | 98.82 Million USD | 2.8% |
| 2021 Q3 | 96.13 Million USD | 4.96% |
| 2021 Q2 | 91.58 Million USD | 15.3% |
| 2021 FY | 365.97 Million USD | 3.42% |
| 2021 Q1 | 79.43 Million USD | -7.35% |
| 2020 FY | 353.87 Million USD | 15.46% |
| 2020 Q3 | 86.32 Million USD | -2.53% |
| 2020 Q2 | 88.56 Million USD | -5.02% |
| 2020 Q1 | 93.24 Million USD | 6.09% |
| 2020 Q4 | 85.73 Million USD | -0.69% |
| 2019 FY | 306.48 Million USD | 21.99% |
| 2019 Q2 | 72.25 Million USD | 11.46% |
| 2019 Q1 | 64.82 Million USD | -3.0% |
| 2019 Q4 | 87.89 Million USD | 7.84% |
| 2019 Q3 | 81.5 Million USD | 12.8% |
| 2018 Q4 | 66.83 Million USD | 3.7% |
| 2018 FY | 251.24 Million USD | 57.82% |
| 2018 Q2 | 62.31 Million USD | 8.07% |
| 2018 Q3 | 64.44 Million USD | 3.42% |
| 2018 Q1 | 57.65 Million USD | 8.22% |
| 2017 Q4 | 53.28 Million USD | 24.59% |
| 2017 Q2 | 35.55 Million USD | 28.84% |
| 2017 Q3 | 42.76 Million USD | 20.26% |
| 2017 FY | 159.2 Million USD | 95.77% |
| 2017 Q1 | 27.59 Million USD | 15.9% |
| 2016 Q1 | 16.06 Million USD | 7.31% |
| 2016 Q2 | 19.72 Million USD | 22.81% |
| 2016 Q3 | 21.72 Million USD | 10.15% |
| 2016 Q4 | 23.81 Million USD | 9.61% |
| 2016 FY | 81.32 Million USD | 61.72% |
| 2015 Q3 | 13.26 Million USD | 10.92% |
| 2015 Q4 | 14.96 Million USD | 12.86% |
| 2015 Q2 | 11.95 Million USD | 18.35% |
| 2015 FY | 50.28 Million USD | 89.39% |
| 2015 Q1 | 10.1 Million USD | 12.07% |
| 2014 Q2 | 5.85 Million USD | 32.83% |
| 2014 Q3 | 7.28 Million USD | 24.46% |
| 2014 FY | 26.55 Million USD | 156.36% |
| 2014 Q4 | 9.01 Million USD | 23.78% |
| 2014 Q1 | 4.4 Million USD | 7.05% |
| 2013 Q2 | 1.89 Million USD | 10.13% |
| 2013 FY | 10.35 Million USD | 213.18% |
| 2013 Q4 | 4.11 Million USD | 56.23% |
| 2013 Q3 | 2.63 Million USD | 39.29% |
| 2013 Q1 | 1.71 Million USD | 24.69% |
| 2012 Q3 | 1.05 Million USD | 20.57% |
| 2012 Q2 | 875 Thousand USD | 0.0% |
| 2012 FY | 3.3 Million USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | 1.37 Million USD | 30.52% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 100.0% |
| 2009 Q4 | -1000.00 USD | -100.1% |
| 2009 FY | 29 Thousand USD | -86.12% |
| 2009 Q3 | 1.02 Million USD | 16983.33% |
| 2009 Q2 | 6000.00 USD | -75.0% |
| 2009 Q1 | 24 Thousand USD | -83.22% |
| 2008 Q3 | 66 Thousand USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | 209 Thousand USD | -56.64% |
| 2008 Q4 | 143 Thousand USD | 116.67% |
| 2007 Q3 | - USD | -100.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | 482 Thousand USD | 63.95% |
| 2007 Q1 | 108 Thousand USD | 47.95% |
| 2007 Q2 | 374 Thousand USD | 246.3% |
| 2006 Q3 | - USD | -100.0% |
| 2006 Q2 | 100 Thousand USD | -17.36% |
| 2006 Q4 | 73 Thousand USD | 0.0% |
| 2006 Q1 | 121 Thousand USD | 0.0% |
| 2006 FY | 294 Thousand USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | -517.456% |
| Dynavax Technologies Corporation | 232.28 Million USD | -107.666% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 20.599% |
| Perrigo Company plc | 4.65 Billion USD | 89.639% |
| Illumina, Inc. | 4.5 Billion USD | 89.29% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 98.874% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -40469.807% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.673% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 96.781% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -279.691% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 96.323% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | 83.684% |
| Biogen Inc. | 9.83 Billion USD | 95.096% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -173.716% |
| Evolus, Inc. | 202.08 Million USD | -138.699% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -2200.529% |
| bluebird bio, Inc. | 29.49 Million USD | -1535.336% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -314.647% |
| FibroGen, Inc. | 147.75 Million USD | -226.476% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 92.941% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 7352.669% |
| Geron Corporation | 237 Thousand USD | -203433.755% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 73.616% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -20.788% |
| Myriad Genetics, Inc. | 678.4 Million USD | 28.895% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -1229.773% |
| Zoetis Inc. | 8.54 Billion USD | 94.354% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -13682.143% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 87.267% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 80.061% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 95.112% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 38.757% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -5526.677% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | -435.247% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -78.261% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -1443.649% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 61.203% |
| OPKO Health, Inc. | 863.49 Million USD | 44.137% |
| Exelixis, Inc. | 1.83 Billion USD | 73.644% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 74.438% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | -2944.72% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | -93.43% |
| Insmed Incorporated | 305.2 Million USD | -58.048% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 41.83% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -1698.363% |
| TG Therapeutics, Inc. | 233.66 Million USD | -106.441% |
| Incyte Corporation | 3.69 Billion USD | 86.947% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 54.029% |